272 related articles for article (PubMed ID: 9213321)
41. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Eniu A; Palmieri FM; Perez EA
Oncologist; 2005 Oct; 10(9):665-85. PubMed ID: 16249346
[TBL] [Abstract][Full Text] [Related]
42. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
43. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
44. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
45. Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer.
Baltali E; Ozişik Y; Güler N; Firat D; Altundağ K
Tumori; 2001; 87(1):18-9. PubMed ID: 11669551
[TBL] [Abstract][Full Text] [Related]
46. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
47. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Mattson K; Saarinen A; Jekunen A
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
[TBL] [Abstract][Full Text] [Related]
48. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
49. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
50. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Aapro MS
Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Pivot X; Asmar L; Hortobagyi GN
Int J Oncol; 1999 Aug; 15(2):381-6. PubMed ID: 10402251
[TBL] [Abstract][Full Text] [Related]
52. [A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Emoto T; Yoshikawa K; Fujikawa M; Fujii M; Yoshioka Y; Hamada E; Naka Y; Komaki T
Gan To Kagaku Ryoho; 2002 May; 29(5):791-4. PubMed ID: 12040687
[TBL] [Abstract][Full Text] [Related]
53. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
54. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
55. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Chou TC; Otter GM; Sirotnak FM
Cancer Chemother Pharmacol; 1996; 37(3):222-8. PubMed ID: 8529281
[TBL] [Abstract][Full Text] [Related]
56. [Taxotere as second-line for metastatic breast cancer].
Culine S
Rev Med Interne; 1999 Mar; 20(3):277-80. PubMed ID: 10216887
[TBL] [Abstract][Full Text] [Related]
57. No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay.
Maeda S; Saikawa Y; Kubota T; Aoki M; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2003; 23(4):3147-50. PubMed ID: 12926047
[TBL] [Abstract][Full Text] [Related]
58. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
59. Expanding options in breast cancer.
Crown JP
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S19-24. PubMed ID: 10630364
[TBL] [Abstract][Full Text] [Related]
60. Taxanes in combined-modality therapy for solid tumors.
Choy H
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):23-38. PubMed ID: 10550824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
